Literature DB >> 1348807

Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group.

R MacKie1, J A Hunter, T C Aitchison, D Hole, K Mclaren, R Rankin, K Blessing, A T Evans, A W Hutcheon, D H Jones.   

Abstract

The Scottish Melanoma Group (SMG) was established in 1979 to assess mortality from and incidence, features, pathological data, and management of cutaneous malignant melanoma in Scotland. Incidence during the first five years and five-year survival have already been reported. We now have data about incidence and mortality over eleven years in relation to anatomical site and pathological types. From 1979 to 1989, 1354 male and 2459 female patients with primary cutaneous malignant melanomas were first diagnosed in Scottish residents. The incidence rate per 100,000 population per year has increased from 3.4 in 1979 to 7.1 in 1989 for men, and from 6.6 to 10.4 for women. The overall increase over eleven years is 82% (7.4% per year). The greatest rates of increase are seen in lesions of the superficial spreading histogenetic type, arising on the female leg and the male trunk. Following public education programmes started in 1985, the proportion of all melanomas less than 1.5 mm thick has shown a sustained and significant increase. Mortality data for 1661 patients for whom a minimum of five-year follow-up is available shows five-year survival of 71.6% overall (77.6% for women, 58.7% for men). The survival advantage for women persists when appropriate statistical adjustment is made for thickness, ulceration, and histogenetic type. These data are useful in designing public education programmes aimed at both primary and secondary prevention of melanoma and in auditing changes in trends that might result from such education.

Entities:  

Mesh:

Year:  1992        PMID: 1348807     DOI: 10.1016/0140-6736(92)91539-k

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Economic evaluation of an educational campaign for early diagnosis of cutaneous melanoma.

Authors:  L Garattini; T Cainelli; G Tribbia; D Scopelliti
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

2.  Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status.

Authors:  R M MacKie; D J Hole
Journal:  BMJ       Date:  1996-05-04

3.  Follow up of patients with colorectal cancer: no simple solutions.

Authors:  J M Gollock
Journal:  Br J Gen Pract       Date:  1995-06       Impact factor: 5.386

4.  Multiple primary melanoma: risk factors and prognostic implications.

Authors:  A D Burden; J P Vestey; J M Sirel; T C Aitchison; J A Hunter; R M MacKie
Journal:  BMJ       Date:  1994-08-06

5.  Clinical melanoma characteristics and survival-a single-center retrospective study between 2000 and 2010.

Authors:  Valentin Feichtenschlager; Felix Weihsengruber; Leo Richter; Igor Vujic; Klemens Rappersberger; Christian Posch
Journal:  Wien Med Wochenschr       Date:  2019-01-16

6.  The UK Government two-week rule and its impact on melanoma prognosis: an evidence-based study.

Authors:  M D Pacifico; R A Pearl; R Grover
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

Review 7.  Skin cancer. Recognition and treatment.

Authors:  R Marks; R J Motley
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

8.  Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity.

Authors:  A M Goldstein; N C Dracopoli; M Engelstein; M C Fraser; W H Clark; M A Tucker
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

Review 9.  Current melanoma epidemic: a nonmetastasizing form of melanoma?

Authors:  R C Burton; B K Armstrong
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

10.  Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients.

Authors:  S Kruijff; E Bastiaannet; A B Francken; M Schaapveld; M van der Aa; H J Hoekstra
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.